154 related articles for article (PubMed ID: 7321322)
21. [The usefulness of early whole body bone scintigraphy in the detection of bone metastasis from prostatic cancer].
Otsuka N; Fukunaga M; Furukawa Y; Tanaka H
Kaku Igaku; 1994 Jun; 31(6):541-50. PubMed ID: 7520953
[TBL] [Abstract][Full Text] [Related]
22. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
[TBL] [Abstract][Full Text] [Related]
23. Prostatic acid phosphatase in serum and bone marrow in patients with prostatic carcinoma.
Fossà SD; Skinningsrud A; Kaalhus O; Engeset A
Br J Urol; 1983 Jun; 55(3):306-11. PubMed ID: 6850249
[TBL] [Abstract][Full Text] [Related]
24. [Clinical evaluation of bone metastases from carcinoma of the prostate by bone scintigraphy with 99mTc-phosphorous compounds (author's transl)].
Bussaka H; Fujimura N; Yamasaki K
Kaku Igaku; 1980 Apr; 17(3):297-303. PubMed ID: 7392308
[No Abstract] [Full Text] [Related]
25. [Radioimmunoassay kit for human prostate acid phosphatase--experimental and clinical evaluation of RIA-Quant P.A.P. Test Kit].
Wakabayashi K; Sugiyama Y; Takahashi E; Shida K
Kaku Igaku; 1982 Apr; 19(3):467-75. PubMed ID: 6182321
[No Abstract] [Full Text] [Related]
26. [What is the use of the radioimmunoassay of prostatic acid phosphatase?].
Luckacs B; Cohen L; Coloby P; Gattegno B; Michel F; Agnes E; Roland J; Thibault P
J Urol (Paris); 1985; 91(4):211-4. PubMed ID: 2410516
[TBL] [Abstract][Full Text] [Related]
27. [Correlation and development of the enzyme activity of phosphatases and the gammagraphic distribution of bone deposits in prostatic cancer (preliminary study)].
Maganto Pavón E; Mateos Torres JA; Verdú Tartajo F; Boronat Tormo F; Mayayo Dehesa T; Romero Aguirre C
Actas Urol Esp; 1981; 5(2):93-8. PubMed ID: 7270286
[No Abstract] [Full Text] [Related]
28. The bone scan as a monitor of prostatic cancer.
Stone AR; Merrick MV; Chisholm GD
Clin Oncol; 1980 Dec; 6(4):349-60. PubMed ID: 7460409
[No Abstract] [Full Text] [Related]
29. [Measurement of serum prostatic acid phosphatase (PAP) by Delfia PAP Kit using europium and clinical evaluation in patients with prostate cancer].
Akimoto S; Ohki T; Ichikawa T; Akakura K; Shimazaki J
Hinyokika Kiyo; 1994 Nov; 40(11):987-93. PubMed ID: 7530404
[TBL] [Abstract][Full Text] [Related]
30. Comparative examination of three radioimmunoassay kits for human prostatic acid phosphatase.
Wakabayashi K; Sugiyama Y; Shida K
Prostate Suppl; 1981; 1():71-8. PubMed ID: 7342071
[TBL] [Abstract][Full Text] [Related]
31. [Clinical evaluation of bone scintigraphy in patients with prostatic cancer].
Murai N; Jinnouchi S; Hoshi H; Watanabe K; Shinkawa T
Kaku Igaku; 1986 Feb; 23(2):115-22. PubMed ID: 3712853
[No Abstract] [Full Text] [Related]
32. [Studies on prognosis of prostate cancer with bone metastasis by using pretreatment bone scintigraphy].
Kubota Y; Numasawa K; Suzuki H; Kakizaki H; Suzuki K
Hinyokika Kiyo; 1989 Oct; 35(10):1693-9. PubMed ID: 2610178
[TBL] [Abstract][Full Text] [Related]
33. [Fundamental and clinical studies on the determination of serum prostatic acid phosphatase by radioimmunoassay--Dainabot PAP-RIA kit].
Hoda T; Ishigami T; Sato S; Ishibashi A; Furuya S; Yokoyama E
Kaku Igaku; 1982 Dec; 19(10):1565-71. PubMed ID: 7169690
[No Abstract] [Full Text] [Related]
34. [Prostatic acid phosphatase by enzymeimmunoassay].
Masukagami T; Ando K; Shimazaki J
Hinyokika Kiyo; 1984 Nov; 30(11):1691-5. PubMed ID: 6084950
[TBL] [Abstract][Full Text] [Related]
35. [Experimental and clinical investigations of bone scintigraphy using 99mTc methylene diphosphonate kit].
Tonami N; Seto M; Ueno K; Kubota A; Hisada K
Kaku Igaku; 1977 Dec; 14(6):911-21. PubMed ID: 614448
[No Abstract] [Full Text] [Related]
36. [Prostate specific antigen in serum of the patients with prostatic cancer].
Akimoto S; Akakura K; Fuse H; Shimazaki J
Hinyokika Kiyo; 1988 Apr; 34(4):636-42. PubMed ID: 2456678
[TBL] [Abstract][Full Text] [Related]
37. Radioimmunoassay versus counterimmune electrophoresis for measurement of serum prostatic acid phosphatase.
Wright GL; Schellhammer PF; Leffell MS; Sieg SM; Brassil BN
Urology; 1982 Apr; 19(4):351-5. PubMed ID: 7072025
[TBL] [Abstract][Full Text] [Related]
38. [Clinical application of immunoenzyme assay for prostatic acid phosphatase].
Yoshida K; Sato S; Nishimura T; Akimoto M
Hinyokika Kiyo; 1989 Oct; 35(10):1819-22. PubMed ID: 2692448
[TBL] [Abstract][Full Text] [Related]
39. [Usefulness of bone gammagraphy versus tumor markers (PSA/PAP) in monitoring cancer of the prostate].
Morote J; de Torres JA
Actas Urol Esp; 1990; 14(4):268-70. PubMed ID: 1702258
[TBL] [Abstract][Full Text] [Related]
40. Staging of prostatic carcinoma with radionuclide bone scintigraphy and lymphography.
Hayward SJ; McIvor J; Burdge AH; Jewkes RF; Williams G
Br J Radiol; 1987 Jan; 60(709):79-81. PubMed ID: 3814999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
